INMBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Inmune Bio, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$1.54−0.03 (-1.91%)
Close on Oct 19, 2026
- Market cap
- $41.15M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$0.31 (−16.76%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Inmune Bio, Inc. grew revenue 257.1% to $50.00K over fiscal 2025. Free cash flow was -$23.62M.
Revenue
$50.00K
+257.1% vs. a year earlier
Operating income
-$20.20M
TTM Q2 2026
Free cash flow
-$23.62M
FY2025
EPS, diluted
-$0.69
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Jun 30, 2026
Valuation
- Market cap
- $41.15M
- P/E ratio
- –
- Price to sales
- 822.93
- Price to book
- 2.02
- Dividend yield
- –
- Free cash flow yield
- -57.41%
Fundamentals
- Revenue
- $50.00K
- Net income
- -$18.42M
- EPS, diluted
- -$0.69
- Free cash flow
- -$23.62M
- Book value per share
- $0.76
- Diluted shares
- 27M
Ten years at a glance
Fiscal years 2016 to 2025 and trailing twelve months, USD
Revenue
–
Operating income
-$20.20M
Net income
-$18.42M
EPS, diluted
-$0.69
Free cash flow
–
Reported periodTrailing twelve months